In the anti-HER2 targeted therapy group, age, menopausal status, surgical method, axillary lymph node dissection method, LVI status, tumor size, histological grade, hormone receptor status, and Ki67 levels were included in univariate analysis as prognostic factors. This evidence concerns the gene ERBB2 and neoplasm.